Insider Selling: ACADIA Pharmaceuticals (NASDAQ:ACAD) EVP Sells $169,621.00 in Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Mark Schneyer sold 5,849 shares of the business’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $29.00, for a total value of $169,621.00. Following the sale, the executive vice president owned 67,828 shares in the company, valued at approximately $1,967,012. The trade was a 7.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ACADIA Pharmaceuticals Stock Performance

ACADIA Pharmaceuticals stock opened at $29.21 on Monday. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $19.69 and a fifty-two week high of $29.48. The firm has a market capitalization of $5.03 billion, a price-to-earnings ratio of 13.16, a price-to-earnings-growth ratio of 23.76 and a beta of 0.81. The stock’s fifty day moving average is $24.39 and its two-hundred day moving average is $23.26.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.11. ACADIA Pharmaceuticals had a return on equity of 9.03% and a net margin of 33.42%.The business had revenue of $308.00 million during the quarter, compared to the consensus estimate of $296.55 million. During the same quarter in the previous year, the company posted $0.16 EPS. The business’s revenue was up 16.4% on a year-over-year basis. As a group, sell-side analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.57 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ACAD. Wall Street Zen raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday. HC Wainwright reissued a “buy” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday. Canaccord Genuity Group lifted their price objective on ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Stifel Nicolaus upped their target price on ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the company a “hold” rating in a research note on Tuesday, July 21st. Finally, Citigroup reiterated a “market outperform” rating on shares of ACADIA Pharmaceuticals in a report on Wednesday. Fourteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.44.

ACADIA Pharmaceuticals News Summary

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its long-term earnings outlook. The firm increased its EPS forecasts to $0.56 for FY2026, $2.95 for FY2028, $3.28 for FY2029 and $3.42 for FY2030, while maintaining a Buy rating. The revisions imply confidence in ACADIA’s earnings growth trajectory. HC Wainwright earnings estimate revisions
• Positive Sentiment: Citizens JMP raised its ACADIA price target to $36. The higher target provides additional upside relative to the recent trading level and reinforces the bullish tone surrounding the stock. Citizens JMP raises ACADIA price target
• Positive Sentiment: Recent results exceeded expectations. ACADIA reported quarterly EPS of $0.18 versus a $0.07 consensus estimate and revenue of $308 million versus expectations of $296.55 million. Revenue increased 16.4% year over year, supporting the view that operating momentum is improving. ACADIA reaches new 52-week high after earnings beat
• Positive Sentiment: Rising earnings estimates are supporting the stock. Zacks highlighted ACADIA among healthcare companies with strong earnings momentum and said recent estimate revisions could support further near-term gains. Zacks ACADIA earnings estimate outlook
• Neutral Sentiment: A separate Zacks analysis compares ACADIA’s year-to-date performance with Amneal Pharmaceuticals and the broader medical sector, providing performance context rather than a new company-specific catalyst. ACADIA performance comparison
• Negative Sentiment: HC Wainwright trimmed its Q4 2026 EPS estimate slightly to $0.20 from $0.21 and used a Hold rating in one related note, signaling some caution around near-term results. HC Wainwright quarterly estimate update

Institutional Trading of ACADIA Pharmaceuticals

Several institutional investors have recently made changes to their positions in ACAD. BlackRock Inc. acquired a new stake in shares of ACADIA Pharmaceuticals during the 2nd quarter worth $569,634,000. Pallas Capital Advisors LLC purchased a new stake in ACADIA Pharmaceuticals during the second quarter valued at about $293,000. Deutsche Bank AG purchased a new stake in ACADIA Pharmaceuticals during the second quarter valued at about $6,521,000. Rice Hall James & Associates LLC acquired a new stake in ACADIA Pharmaceuticals during the second quarter worth about $15,658,000. Finally, Uniting Wealth Partners LLC acquired a new stake in ACADIA Pharmaceuticals during the second quarter worth about $278,000. 96.71% of the stock is owned by hedge funds and other institutional investors.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.